Literature DB >> 7937548

Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep.

H Schreier1, K J McNicol, D B Bennett, Z Teitelbaum, H Derendorf.   

Abstract

The unanesthetized awake sheep was employed as large animal model for the determination of bioavailability and pharmacokinetics following the pulmonary instillation of the decapeptide detirelix. After intratracheal administration of a 80 micrograms/kg dose, the average t1/2 of elimination was 9.8 +/- 1.3 hours (n = 5) which was similar to the elimination kinetics of a 30 micrograms/kg i.v. dose (7.2 +/- 2.9 hours). Mean residence time (MRT) was prolonged to 10.3 +/- 2.0 hours vs. 2.7 +/- 0.8 hours i.v., and mean absorption time (MAT) was calculated to be 7.5 +/- 1.8 hours. Maximum plasma levels (cmax) of 9.2 ng/ml were reached after 2 hours. The average bioavailability was 9.8 +/- 3.9% of the dose. The pharmacokinetic profile was found to be similar after aerosol administration. It was concluded that detirelix was absorbed systemically when administered by pulmonary instillation or aerosolization and that the unanesthetized awake sheep is a suitable model to study resulting drug profiles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937548     DOI: 10.1023/a:1018951824315

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Passage of aerosolized BSA and the nona-peptide dDAVP via the respiratory tract in young and adult rats.

Authors:  H G Folkesson; B R Weström; M Dahlbäck; S Lundin; B W Karlsson
Journal:  Exp Lung Res       Date:  1992 Sep-Oct       Impact factor: 2.459

2.  Radioimmunoassay of detirelix ([ N-Ac-D-Nal(2)1,D-p-Cl-Phe2,D-Trp3, D-hArg(Et)6(2),D-Ala10]-luteinizing hormone-releasing hormone) in plasma or serum.

Authors:  C Nerenberg; J LaFargue; A Webb; R Chan; S Kushinsky
Journal:  J Immunoassay       Date:  1988

3.  Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys.

Authors:  R L Chan; W Ho; A S Webb; J A LaFargue; C A Nerenberg
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

4.  The flow-past chamber: an improved nose-only exposure system for rodents.

Authors:  W C Cannon; E F Blanton; K E McDonald
Journal:  Am Ind Hyg Assoc J       Date:  1983-12

Review 5.  The isolated perfused lung--a critical evaluation.

Authors:  H M Mehendale; L S Angevine; Y Ohmiya
Journal:  Toxicology       Date:  1981       Impact factor: 4.221

6.  Endocytosis in alveolar type II cells: effect of charge and size of tracers.

Authors:  M C Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

7.  Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men.

Authors:  S N Pavlou; G B Wakefield; D P Island; P G Hoffman; M E LePage; R L Chan; C A Nerenberg; W J Kovacs
Journal:  J Clin Endocrinol Metab       Date:  1987-05       Impact factor: 5.958

8.  Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.

Authors:  N I Chu; R L Chan; K M Hama; M D Chaplin
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

9.  Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog.

Authors:  D B Bennett; E Tyson; C A Nerenberg; S Mah; J S de Groot; Z Teitelbaum
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

View more
  2 in total

1.  Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog.

Authors:  D B Bennett; E Tyson; C A Nerenberg; S Mah; J S de Groot; Z Teitelbaum
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

Review 2.  The lung as a route for systemic delivery of therapeutic proteins and peptides.

Authors:  R U Agu; M I Ugwoke; M Armand; R Kinget; N Verbeke
Journal:  Respir Res       Date:  2001-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.